

YOU ARE INVITED

NEW THERAPIES IN MANAGING ADVANCED PROSTATE CANCER

NEW ENGLAND SECTION SATELLITE SYMPOSIUM

SEAPORT WORLD TRADE CENTER BOSTON

BOSTON, MASSACHUSETTS

Friday, September 28, 2007

Harborview 1

FACULTY

Sam S. Chang, MD

Associate Professor
Vanderbilt University School of Medicine
Nashville, Tennessee

Samir S. Taneja, MD

Associate Professor of Urologic Oncology
Director, Urologic Oncology
New York University School of Medicine
New York, New York

Registration and Full International Breakfast 6:00 AM - 6:45 AM

Scientific Program 6:45 AM - 7:50 AM

CONTRIBUTING FACULTY

Herbert Lepor, MD (Chairman)
Professor and Martin Spatz Chairperson of
Urology and Professor of Pharmacology
New York University School of Medicine
New York, New York

Michael K. Brawer, MD
Chief Medical Officer
Threshold Pharmaceuticals
Redwood City, California

Daniel J. George, MD
Associate Professor of Medicine and Surgery
Duke University Medical Center
Durham, North Carolina

Simon J. Hall, MD (Co-Chair)
Director, Deane Prostate Health & Research
Center
Chairman, Department of Urology
Mount Sinai School of Medicine
New York, New York

Sam S. Chang, MD
Associate Professor
Vanderbilt University School of Medicine
Nashville, Tennessee

Samir S. Taneja, MD
Associate Professor of Urologic Oncology
Director, Urologic Oncology
New York University School of Medicine
New York, New York

E. David Crawford, MD
Professor of Oncology/Radiation Oncology
University of Colorado
Aurora, Colorado

Johannes Vieweg, MD
Professor and Chair - Urology
University of Florida - Gainesville
Gainesville, Florida

SPONSORED BY:



Postgraduate Institute
for Medicine

SUPPORTED BY AN UNRESTRICTED
EDUCATIONAL GRANT FROM:

WatsonUrology

A Speciality of Watson Pharmaceuticals, Inc.



COORDINATED BY:

MEDREVIEWS

Target Audience

This activity has been designed to meet the educational needs of urologists involved in the care of patients with advanced prostate cancer.

Statement of Need/Program Overview

Androgen-deprivation therapy is universally accepted as first-line treatment of symptomatic metastatic prostate cancer, and recently developed agents with different dosing regimens and routes of administration have increased the potency of this therapeutic approach. This program addresses the latest developments in hormonal therapy and chemotherapy for what remains the second leading cause of cancer-related mortality among men. Recognizing the fact that many prostate cancers eventually become hormone-resistant, the program reviews advances in development of non-hormonal therapies within the past few years. Topics include the rationale and strategy for gene and immune-based therapies as well as a treatment algorithm designed to optimize the management of patients with advanced prostate cancer.

Educational Objectives

After completing this activity, the participant should be better able to:

- Describe the most recent advances in hormonal therapy and chemotherapy for advanced prostate cancer, including gene and immune-based therapies.
- Outline the unresolved controversies regarding metastatic prostate cancer treatment.
- Review the strengths, limitations, and potential side effects of new treatments.
- Differentiate the most effective uses of these new treatments for the individual patient.
- Describe the most promising ongoing research into management of advanced prostate cancer.

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and MedReviews, LLC. PIM is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Postgraduate Institute for Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The *faculty* reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

<i>Name of Faculty or Presenter</i>	<i>Reported Financial Relationship</i>
Michael K. Brawer, MD	Consulting Fees: Watson Pharmaceuticals Other: Part owner MedReviews, LLC
Sam S. Chang, MD	Consulting Fees: Watson Pharmaceuticals Non-CME Services: Sanofi-Aventis
E. David Crawford, MD	Consulting Fees: Auxilium Pharmaceuticals, Cell Genesys, GPC Biotech, Endocore, Watson Pharmaceuticals Non-CME Services: GlaxoSmithKline Contracted Research: Univ. of Colorado, WIH
Daniel J. George, MD	Consulting Fees (eg., advisory boards): GSK, Novartis, Pfizer Fees for Non-CME Services Received Directly from a Commercial Interest or their Agents (eg., speakers' bureau): Sanofi-Aventis, Pfizer Contracted Research: Pfizer, Novartis, GSK, Dendreon
Simon J. Hall, MD	Contracted Research: Dendreon
Herbert Lepor, MD	Consulting Fees: Watson Pharmaceuticals
Samir S. Taneja, MD	Consulting Fees: Watson Pharmaceuticals
Johannes Vieweg, MD	No real or apparent conflicts of interest to report

The *planners and managers* reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

<i>Name of Planner or Manager</i>	<i>Reported Financial Relationship</i>
Trace Hutchison, PharmD, Postgraduate Institute for Medicine	No real or apparent conflicts of interest to report

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM), MedReviews, LLC, and Watson Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, MedReviews, LLC, and Watson Pharmaceuticals. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.